- Home
- SM vs FOLD Comparison
SM vs FOLD Comparison
Compare SM & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SM
- FOLD
- Stock Information
- Founded
- SM 1908
- FOLD 2002
- Country
- SM United States
- FOLD United States
- Employees
- SM N/A
- FOLD N/A
- Industry
- SM Oil & Gas Production
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- SM Energy
- FOLD Health Care
- Exchange
- SM Nasdaq
- FOLD Nasdaq
- Market Cap
- SM 3.0B
- FOLD 2.5B
- IPO Year
- SM 1992
- FOLD 2007
- Fundamental
- Price
- SM $25.24
- FOLD $8.26
- Analyst Decision
- SM Hold
- FOLD Strong Buy
- Analyst Count
- SM 11
- FOLD 9
- Target Price
- SM $42.44
- FOLD $26.44
- AVG Volume (30 Days)
- SM 2.2M
- FOLD 5.8M
- Earning Date
- SM 10-30-2025
- FOLD 11-05-2025
- Dividend Yield
- SM 3.18%
- FOLD N/A
- EPS Growth
- SM 1.83
- FOLD N/A
- EPS
- SM 7.07
- FOLD N/A
- Revenue
- SM $3,002,621,000.00
- FOLD $571,160,000.00
- Revenue This Year
- SM $33.13
- FOLD $21.04
- Revenue Next Year
- SM N/A
- FOLD $21.34
- P/E Ratio
- SM $3.56
- FOLD N/A
- Revenue Growth
- SM 27.02
- FOLD 25.35
- 52 Week Low
- SM $19.67
- FOLD $5.51
- 52 Week High
- SM $46.42
- FOLD $12.65
- Technical
- Relative Strength Index (RSI)
- SM 42.20
- FOLD 54.64
- Support Level
- SM $24.64
- FOLD $8.03
- Resistance Level
- SM $26.41
- FOLD $8.59
- Average True Range (ATR)
- SM 1.11
- FOLD 0.36
- MACD
- SM -0.15
- FOLD -0.05
- Stochastic Oscillator
- SM 9.73
- FOLD 46.67
About SM SM Energy Company
SM Energy Co is an independent energy company engaged in the acquisition, exploration, development, and production of oil, gas, and NGLs in Texas and Utah. Its portfolio is comprised of assets in the Midland Basin of West Texas, the Maverick Basin of South Texas, and the Uinta Basin of northeastern Utah.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.